drugset / Trial / NCT00321854

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854

Phase 4 Completed 535 enrolled Boehringer Ingelheim
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease

Timeline

Start
2006-05
Primary completion
2009-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 2.25 mg

Indications